Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+
regulatory T cells. These cells might suppress tumor-specific immune responses.
Cyclophosphamide has been shown to reduce the frequency of CD4+CD25+ regulatory T cells. The
aim of this study is to test if the treatment with cyclophosphamide leads to a decrease in
the frequency of CD4+CD25+ regulatory T cells and to increase tumor specific immune responses
in patients with advanced HCC.